Market capitalization | $20.74m |
Enterprise Value | $21.20m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 2.44 |
P/S ratio (TTM) P/S ratio | 2.39 |
P/B ratio (TTM) P/B ratio | 29.33 |
Revenue growth (TTM) Revenue growth | -59.08% |
Revenue (TTM) Revenue | $8.69m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
5 Analysts have issued a Cara Therapeutics Inc forecast:
5 Analysts have issued a Cara Therapeutics Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 8.69 8.69 |
59%
59%
|
|
Gross Profit | 7.18 7.18 |
46%
46%
|
|
EBITDA | -82 -82 |
31%
31%
|
EBIT (Operating Income) EBIT | -82 -82 |
31%
31%
|
Net Profit | -96 -96 |
18%
18%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics. Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.
Head office | United States |
CEO | Christopher Posner |
Employees | 55 |
Founded | 2004 |
Website | www.caratherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.